News
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® ...
12h
Everyday Health on MSNFDA Approves a ‘Game-Changing’ Twice-a-Year HIV Prevention ShotThe new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.
2d
India Today on MSNLenacapavir becomes first FDA-approved HIV preventive drug: All about itThe US FDA has approved lenacapvir, sold under the brand name Yeztugo, as the first preventive treatment against HIV. It is a ...
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
2d
GlobalData on MSNGilead Sciences’ Yeztugo receives approval from US FDA for HIVThe US Food and Drug Administration (FDA) has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a ...
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...
The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...
12h
HealthDay on MSNFDA Approves Twice-Yearly Yeztugo for Preexposure Prophylaxis to Cut HIV RiskThe U.S. Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as ...
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.
Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results